Evidence map›Paper›PMID 41763534›Full record

ArticleThe American journal of pathology2026

Epidermal Growth Factor Receptor/KIT-Linked Proliferative Bias in Normal Breast Lobules from Matched Non-Hispanic Black and White Women Is Rapidly Reversible by Receptor Tyrosine Kinase Inhibition.

Joshua W Ogony, Nicole Cruz-Reyes, Laura Pacheco-Spann, Amanda Arnold, Sarah McLaughlin, Amy C Degnim, Stacey J Winham, Mark E Sherman, Derek C Radisky

Abstract read
In one paragraph

Article in The American journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joshua W OgonyDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, Florida; Department of Quantitative Health Sciences, Mayo Clinic College of Medicine, Jacksonville, Florida.
Nicole Cruz-ReyesDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, Florida.
Laura Pacheco-SpannDepartment of Quantitative Health Sciences, Mayo Clinic College of Medicine, Jacksonville, Florida.
Amanda ArnoldDepartment of Research, Mayo Clinic College of Medicine, Jacksonville, Florida.
Sarah McLaughlinDepartment of Surgery, Mayo Clinic College of Medicine, Jacksonville, Florida.
Amy C DegnimDepartment of Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota.
Stacey J WinhamDepartment of Quantitative Health Sciences, Mayo Clinic College of Medicine, Rochester, Minnesota.
Mark E ShermanDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, Florida; Department of Quantitative Health Sciences, Mayo Clinic College of Medicine, Jacksonville, Florida.
Derek C RadiskyDepartment of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, Florida. Electronic address: radisky.derek@mayo.edu.

Funding

Predicting Breast Cancer Risk after Benign Percutaneous BiopsyR01CA229811 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, SHERMAN, MARK E · 2018 to 2022
$3.5M
Involution-based biomarkers of breast cancer riskR01CA237602 · NCI · MAYO CLINIC JACKSONVILLE · PI DEGNIM, AMY C, RADISKY, DEREK C · 2020 to 2024
$2.8M
NCI NIH HHS R01 CA229811NCI NIH HHS R01 CA237602
6 · The paper itself

Abstract

Basal-like/triple-negative breast cancers occur disproportionately at younger ages among non-Hispanic Black women (NHBW), but whether normal breast epithelium shows measurable, reversible differences in proliferative signaling is unclear. Histologically normal lobules from parity-, age-, and body mass index-matched NHBW and non-Hispanic White women (NHWW) donors (10 versus 10) were profiled using targeted transcriptomics (IO360/BC360) and whole-slide quantitative immunohistochemistry for epidermal growth factor receptor (EGFR), KIT, and cytokeratin-5. Eighty-nine transcripts differed between groups at false discovery rate < 0.10, with EGFR and KIT elevated in NHBW lobules and enrichment of basal/receptor tyrosine kinase-linked programs. Quantitative immunohistochemistry confirmed higher protein in NHBW tissue; in lobule-level models, the group effect (NHBW - NHWW) was EGFR β = 0.055, P = 0.010; KIT β = 0.093, P = 0.0027; and cytokeratin-5 β = 0.126, P = 0.027. In prestasis human mammary epithelial cells, 24-hour treatment with EGFR (lapatinib) or KIT (ripretinib) inhibitors increased cyclin-dependent kinase inhibitors, decreased cyclins/cyclin-dependent kinase 4/6, and enforced G

Indexed as

BreastErbB ReceptorsProtein Kinase InhibitorsProto-Oncogene Proteins c-kitAdultBlack or African AmericanBreast NeoplasmsCell ProliferationFemaleHumansMiddle AgedWhiteEGFR protein, humanErbB ReceptorsKIT protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-kit

Identifiers

PMID41763534
PMCPMC13197954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.